Foreign institutional investors (FIIs) have reduced their shareholding in Wockhardt to 3.71% at the end of March 2014 quarter from 4.86% as on December 31, 2013. On the other hand, domestic institutional investors’ (DIIs) shareholding went up to 4.12% at the end of March 2014 quarter from 3.39% as on December 31, 2013. Meanwhile, promoter and promoter group shareholding was unchanged at 74.70% at the end of March 2014 quarter.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
